Therefore, siRNAs for cyclin B may be an effective treatment against cancers where p53 function is inhibited but the gene has not been deleted.
Therefore, siRNAs targeting cyclin B may be a viable approach against cancers where the p53 pathway is compromised but the gene remains intact.